India, Oct. 4 -- CSL (CSL.AX) and Alentis Therapeutics have entered into an exclusive global collaboration and co-promotion agreement to advance lixudebart, a potential first-in-class therapy targeting claudin-1 for the treatment of rare kidney, liver and other diseases, CSL said in a statement.
The partnership combines Alentis' expertise in claudin-1-targeted therapies with CSL's global development and commercialization capabilities in nephrology, aiming to accelerate the development of innovative treatments for patients with serious and underserved diseases.
Lixudebart is currently being evaluated in the Phase 2 RENAL trial for patients with ANCA-associated vasculitis with rapidly progressive glomerulonephritis (AAV-RPGN), a rare autoim...